Clinical trials: Oral Chemotherapy
Breast Cancer
Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS)
This is an open label, phase II study evaluating the efficacy and safety of trastuzumab combined with oral chemotherapy or endocrine therapy in patients with HER-2 positive stage I breast cancer.
- Trial name
- IRIS (NCT04383275)
- Testing
- capecitabine and trastuzumab, endocrine therapy and trastuzumab
- Where
- China
- Volunteers
- 367 people
- Sponsor
- Fudan University
Oral Mucositis, Carcinoma in Situ of Upper Respiratory Tract
Efficacy of MUCIPLIQ on the Incidence of Radio-chemotherapy-induced Mucositis in Patients Suffering From Oral Cancer
MUCIPLIQ is a nanopolymer engineered to mimic glycosaminoglycans such as heparan sulfates. Glycosaminoglycans are involved 1) in the stabilization of cells micro-environment, known as extracellular matrix, by binding to…
- Trial name
- MUCIPLIQ (NCT01840436)
- Testing
- MUCIPLIQ
- Where
- 5 sites in France
- Volunteers
- 136 people
- Sponsor
- Organ, Tissue, Regeneration, Repair and Replacement
Periodontal Diseases, Chronic Periodontitis
Photodynamic Therapy During Supportive Periodontal Therapy
27 subjects on SPT, each with at least two residual pockets ≥5mm, were recruited for this randomised, split-mouth controlled trial, providing a total of 72 sites.
- Conditions
- Periodontal Diseases, Chronic Periodontitis, Periodontal Attachment Loss
- Trial name
- NCT02666573
- Testing
- Fotosan 630, CMS Dental, Copenhagen, Denmark, Scaling and root planing
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- National University of Singapore
Oral Complications of Chemotherapy and Head and Neck Radiation
Prevalence of Oral Side Effects Associated With Chemo and Radiotherapy for Treating Head and Neck Cancer
A cross-sectional study will be conducted to report oral complications during chemo and radiotherapy treatment in case of patients diagnosed with head and neck cancer and the effect of theses oral side effects on patients'…
- Trial name
- NCT04845854
- Where
- Egypt
- Volunteers
- 294 people
- Sponsor
- Cairo University
Advanced Primary Liver Cancer
Clinical Trial of Elemene in Combination With Oxaliplatinin the Treatment of Advanced Primary Liver Cancer
Clinical Trial of Elemene Injection/Elemene Oral Emulsion in Combination with Systematic Chemotherapy including Oxaliplatin in the First -line treatment of advanced primary liver cancer
- Trial name
- NCT03166553
- Testing
- Elemene
- Where
- 10 sites in China
- Volunteers
- 150 people
- Sponsor
- BeiJing Yijiayi Medicine Techonoloy Co., Ltd.
Head and Neck Cancer
S0011, Gene Therapy & Surgery Followed by Chemo & RT in Newly Diagnosed Cancer of the Mouth or Throat
RATIONALE: Inserting the p53 gene into a person's cancer cells may improve the body's ability to fight cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00017173
- Testing
- Ad5CMV-p53 gene, cisplatin, conventional surgery
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- SWOG Cancer Research Network
Renal Impairment, Hepatic Impairment
Phase I Open-label Study to Evaluate Pharmacokinetics of TAK-272 in Participants With Renal or Hepatic Impairment
The purpose of this study is to examine the effects of renal and hepatic impairment on TAK-272 pharmacokinetics with a single oral administration of TAK-272 in participants with renal or hepatic impairment.
- Trial name
- NCT02367872
- Testing
- TAK-272
- Where
- 4 sites in Japan
- Volunteers
- 48 people
- Sponsor
- Takeda
Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2)
A Study of TAK-994 in Adults With Type 1 and Type 2 Narcolepsy
The main aims of the study are: To check for side effects from TAK-994 and check what dose of TAK-994 participants can tolerate. To check what dose range provides adequate relief of narcolepsy symptoms.
- Trial name
- NCT04096560
- Testing
- TAK-994
- Where
- 78 sites in United States, Canada and 10 more
- Volunteers
- 97 people
- Sponsor
- Takeda
Gastrointestinal Cancer, Biliary Tract Cancer
Study of D07001-Softgel Capsules in Subjects With Gastrointestinal Cancer in Dose-Escalation Phase and in Subjects With Biliary Tract Cancer in Dose-Expansion Phase
Part 1: Dose-Escalation Phase (Phase 1b) The primary objective is to assess the safety and tolerability of increasing doses of D07001 softgel in patients with unresectable locally advanced or metastatic gastrointestinal (GI)…
- Trial name
- NCT03531320
- Testing
- D07001-softgel capsules
- Where
- 4 sites in Taiwan
- Volunteers
- 19 people
- Sponsor
- InnoPharmax Inc.
Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
This phase II trial tests the addition of chemotherapy, with carboplatin and paclitaxel, or chemo-immunotherapy, with carboplatin, paclitaxel and cemiplimab to standard salvage surgery followed by post operative radiation therapy…
- Conditions
- Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Locally Recurrent Head and Neck Squamous Cell Carcinoma, Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma
- Trial name
- NCT07195734
- Testing
- Biospecimen Collection, Carboplatin, Cemiplimab
- Where
- 115 sites in United States
- Volunteers
- 180 people
- Sponsor
- National Cancer Institute (NCI)
Obesity
Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1 Therapy Discontinuation
This study will compare the effect of orforglipron and phentermine on weight maintenance.
- Trial name
- NCT07729332
- Testing
- Phentermine Pill, Orforglipron
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Massachusetts General Hospital
Head and Neck Cancer, Oral Complications of Radiation Therapy
CD2 Lozenges in Preventing Acute Oral Mucositis in Patients With Head and Neck Cancer Receiving Radiotherapy and Chemotherapy
RATIONALE: Lactobacillus bevis CD2 lozenge may help prevent symptoms of mucositis, or mouth sores, in patients receiving radiation therapy and chemotherapy.
- Conditions
- Head and Neck Cancer, Oral Complications of Radiation Therapy, Pain, Weight Changes
- Trial name
- NCT01545687
- Testing
- Lactobacillus brevis CD2 lozenge
- Sponsor
- Alliance for Clinical Trials in Oncology
Oral Squamous Cell Carcinoma, Squamous Cell Carcinoma of Oropharynx
Laser Mucite ORL : Effectiveness of Laser Therapy for Mucositis Induced by a Radio-chemotherapy in Head and Neck Cancer
The purpose of the study is to assess in a randomized, double blind, controlled, multi-center, phase III study, the efficacy of low level diode laser (100 MW, 658 Nm), in the prevention and treatment of radiochemotherapy-induced…
- Conditions
- Oral Squamous Cell Carcinoma, Squamous Cell Carcinoma of Oropharynx, Squamous Cell Carcinoma of Hypopharynx, Oral Mucositis
- Trial name
- LaserMucite (NCT01772706)
- Testing
- low level laser therapy
- Where
- 6 sites in France
- Volunteers
- 97 people
- Sponsor
- Institut Cancerologie de l'Ouest
Peripheral T-cell Lymphoma (Not Otherwise Specified), Angioimmunoblastic T-cell Lymphoma
Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma
The purpose of this study is to determine whether intravenous Bortezomib combined with oral Panobinostat (LBH589) are effective in treating adult patients with relapsed/refractory peripheral T-cell lymphoma or NK/T-cell lymphoma…
- Conditions
- Peripheral T-cell Lymphoma (Not Otherwise Specified), Angioimmunoblastic T-cell Lymphoma, Extranodal NK/T-cell Lymphoma Nasal Type, Enteropathy- Type T-cell Lymphoma
- Trial name
- NCT00901147
- Testing
- panobinostat and bortezomib
- Where
- 5 sites in Malaysia, Singapore and 1 more
- Volunteers
- 25 people
- Sponsor
- Singapore General Hospital
Unspecified Adult Solid Tumor, Protocol Specific
Chemotherapy in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of temozolomide in treating patients who have advanced…
- Trial name
- NCT00003708
- Testing
- temozolomide
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Oral Cancer, Oropharyngeal Cancer
Evaluation of the Photobiomodulation Using LED Lamp for Curative Treatment of Radio-induced Mucositis.
This is a monocentric, prospective, non-comparative phase II study with minimal risks and constraints. The study will aim to assess the curative treatment of radio-induced mucositis by photobiomodulation using LED lamp.
- Trial name
- MuciLight (NCT04251949)
- Testing
- LED photobiomodulation
- Where
- France
- Volunteers
- 28 people
- Sponsor
- Centre Oscar Lambret
Head and Neck Cancer
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00113399
- Testing
- filgrastim, cisplatin, docetaxel
- Where
- 125 sites in United States
- Volunteers
- 15 people
- Sponsor
- Radiation Therapy Oncology Group
Peripheral Blood Stem Cell Transplantation
Incidence and Factors Associated With the Development and Severity of Oral Mucositis
Our study intends to evaluate prospectively the incidence and severity of oral mucositis in patients undergoing high-dose chemotherapy and hematopoietic stem cell transplantation, as well as to evaluate the potential influence of…
- Trial name
- NCT00575809
- Testing
- Mucositis and nutritional assessments
- Where
- 2 sites in United States
- Volunteers
- 633 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Mouth Neoplasms, Oropharyngeal Neoplasms
F-18 Fluorothymidine PET Imaging for Early Evaluation of Response to Therapy in Head & Neck Cancer Patients
This is an imaging protocol only, not a therapeutic study. The primary goal of the proposed study is to examine the utility of a new imaging study, Positron Emission Tomography with F-18 Fluorothymidine (FLT PET), in the early…
- Conditions
- Mouth Neoplasms, Oropharyngeal Neoplasms, Laryngeal Neoplasms, Head and Neck Neoplasms
- Trial name
- NCT00721799
- Testing
- 18F-Fluorothymidine PET scan
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Iowa
Acute Myeloid Leukemia
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Greece
Acute Myeloid Leukemia (AML) is a cancer of the blood and bone marrow and is the most common acute leukemia in adults. This study will evaluate how well Venetoclax works to treat AML in adult participants who are ineligible for…
- Trial name
- SURVIVE (NCT05317494)
- Where
- 13 sites in Greece
- Volunteers
- 106 people
- Sponsor
- AbbVie